title: HLA-A*0201 is associated with a better outcome after donor lymphocyte infusion for recurrent malignancy.
authors.forename: David
authors.initials: D
authors.lastname: Nachbaur
authors.forename: Olga
authors.initials: O
authors.lastname: Angelova
authors.forename: Klaus
authors.initials: K
authors.lastname: Loacker
authors.forename: Jutta
authors.initials: J
authors.lastname: Auberger
authors.forename: Johannes
authors.initials: J
authors.lastname: Clausen
authors.forename: Petra
authors.initials: P
authors.lastname: Schumacher
authors.forename: Günther
authors.initials: G
authors.lastname: Gastl
authors.forename: Brigitte
authors.initials: B
authors.lastname: Kircher
mesh_terms: D001782:Blood Donors; D015234:HLA-A Antigens / Q000276:immunology*; D015789:HLA-A2 Antigen; D006801:Humans; D007263:Infusions, Parenteral; D007938:Leukemia / Q000276:immunology* / Q000601:surgery / Q000628:therapy*; D017710:Lymphocyte Transfusion; D012008:Recurrence; D033581:Stem Cell Transplantation; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen